Sensus Healthcare Reports 20.7% Revenue Decline in Q2 2025

Sensus Healthcare, Inc. reported a decline in financial performance for the second quarter of 2025, with revenues totaling $7.3 million, down 20.7% from $9.2 million in the same period last year. For the first half of 2025, revenues decreased by 21.1% to $15.7 million compared to $19.9 million in the first half of 2024. The company attributed this decline primarily to a reduced number of units sold to a significant customer. Gross profit also fell sharply, with the company reporting $2.9 million for the second quarter, a decrease of 46.3% year-over-year, resulting in a gross profit margin of 39.7%, down from 58.7% in the prior year.

Operating expenses increased significantly, with total operating expenses for the second quarter rising to $4.8 million, up 40.5% from $3.4 million in the same quarter of 2024. This increase was driven by higher general and administrative costs, which rose by 25% to $2.0 million, and a 66.7% increase in research and development expenses, which reached $1.5 million. The company reported a net loss of $1.0 million for the second quarter, compared to a net income of $1.6 million in the same period last year. For the first half of 2025, the net loss was $3.6 million, a significant decline from the $3.9 million net income reported in the first half of 2024.

In terms of operational metrics, Sensus Healthcare's accounts receivable decreased to $12.6 million as of June 30, 2025, down from $19.7 million at the end of 2024, reflecting the impact of lower sales. Inventory levels increased to $12.4 million, up from $10.1 million, as the company anticipates future sales growth. The company continues to focus on its core product lines, including the SRT-100 and its newer models, while also expanding its operational healthcare services through its subsidiary, Sensus Healthcare Services, LLC.

Looking ahead, Sensus Healthcare remains cautious about market conditions, particularly regarding inflationary pressures and the concentration of sales to a single customer, which accounted for 56% of revenue in the second quarter. The company is actively monitoring these factors and is committed to enhancing its product offerings and expanding its market presence. Management believes that the current liquidity position, with cash and cash equivalents of $22.2 million, along with available borrowing capacity, will support operational needs in the near term. However, the company acknowledges the potential need for additional funding to support future growth initiatives.